Opioid withdrawal resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 38: Line 38:


==Management==
==Management==
===Diagnostic Approach===
Shown below is an algorithm depicting the management of opioid withdrawal.<ref name="Huitink-2003">{{Cite journal  | last1 = Huitink | first1 = J. | last2 = Buitelaar | first2 = D. | title = Management of drug and alcohol withdrawal. | journal = N Engl J Med | volume = 349 | issue = 4 | pages = 405-7; author reply 405-7 | month = Jul | year = 2003 | doi =  | PMID = 12879900 }}</ref>
Shown below is an algorithm depicting the management of opioid withdrawal.<ref name="Huitink-2003">{{Cite journal  | last1 = Huitink | first1 = J. | last2 = Buitelaar | first2 = D. | title = Management of drug and alcohol withdrawal. | journal = N Engl J Med | volume = 349 | issue = 4 | pages = 405-7; author reply 405-7 | month = Jul | year = 2003 | doi =  | PMID = 12879900 }}</ref>
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree/start |summary=Opioid withdrawal diagnosis algorithm.}}
{{familytree | | | A01 |A01=<div style="float: left; text-align: left">'''Characterize the symptoms:''' <br>❑ Flu like illness <br>❑ Lacrimation<br>  ❑ Rhinorrhea <br>❑ Sneezing<br> ❑ Yawning <br> ❑ [[Anorexia]] <br> ❑ [[Nausea]]<br> ❑ Vomiting<br> ❑ Abdominal cramps<br> ❑ [[Diarrhea]]<br> ❑ [[Myalgia]]<br> ❑ [[Arthralgia]] </div>}}  
{{familytree | | | A01 |A01=<div style="float: left; text-align: left">'''Characterize the symptoms:''' <br>❑ Flu like illness <br>❑ Lacrimation<br>  ❑ Rhinorrhea <br>❑ Sneezing<br> ❑ Yawning <br> ❑ [[Anorexia]] <br> ❑ [[Nausea]]<br> ❑ Vomiting<br> ❑ Abdominal cramps<br> ❑ [[Diarrhea]]<br> ❑ [[Myalgia]]<br> ❑ [[Arthralgia]] </div>}}  
{{familytree | | | |!| | | | | | | | }}
{{familytree | | | |!| | | | | | | | }}
Line 46: Line 47:
{{familytree | | | X01 | | | | | | | | | |X01=<div style="float: left; text-align: left">'''Consider alternative diagnosis:''' <br> ❑ Alcohol withdrawal <br> ❑ [[Sedative-hypnotic|Sedative hypnotic withdrawal]] <br> ❑ [[Cholinergic|Cholinergic poisoning]] <br> ❑ [[Sympathomimetic|Sympathomimetic intoxication]] </div>}}
{{familytree | | | X01 | | | | | | | | | |X01=<div style="float: left; text-align: left">'''Consider alternative diagnosis:''' <br> ❑ Alcohol withdrawal <br> ❑ [[Sedative-hypnotic|Sedative hypnotic withdrawal]] <br> ❑ [[Cholinergic|Cholinergic poisoning]] <br> ❑ [[Sympathomimetic|Sympathomimetic intoxication]] </div>}}
{{familytree | | | |!| | | | | | | | | | | }}
{{familytree | | | |!| | | | | | | | | | | }}
{{familytree | | | C01 | | | | | | | | | |C01=❑ Admit the patient }}
{{familytree | | | C01 | | | | | | | | | |C01=<div style="float: left; text-align: left">'''[[Opioid#Dependence|Diagnostic criteria:]]'''<br>A. Either of the following
:❑ Cessation of or reduction in opioid use that has been heavy and for several weeks or longer
:❑ Administration of an opioid antagonist after a period of opioid use<br>
❑ B. Three or more of the following (developing within minutes to several days after criterion A)
:❑ Diarrhea
:❑ Dysphoric mood
:❑ Fever
:❑ Insomnia
:❑ Lacrimation or rhinorrhea
:❑ Muscle aches
:❑ Nausea or vomiting
:❑ Pupillary dilation, piloerection, or sweating
:❑ Yawning</div>}}
{{familytree | | | |!| | | | | | | | | | | }}
{{familytree | | | |!| | | | | | | | | | | }}
{{familytree | | | D01 | | | | | | | | | |D01=<div style="float: left; text-align: left">❑ '''Start opioid agonists:'''<ref name="Huitink-2003">{{Cite journal  | last1 = Huitink | first1 = J. | last2 = Buitelaar | first2 = D. | title = Management of drug and alcohol withdrawal. | journal = N Engl J Med | volume = 349 | issue = 4 | pages = 405-7; author reply 405-7 | month = Jul | year = 2003 | doi = | PMID = 12879900 }}</ref><br>
{{familytree | | | D01 | | | | | | | | | | |D01=<div style="float: left; text-align: left">'''Consider treatment with:'''<br>❑ Opioid maintenance treatment<br>'''or'''<br>❑ Medically supervised withdrawal (detoxification)</div>}}
:❑ Methadone (pure agonist) 20-35 mg daily, or<br>
{{familytree/end}}
:❑ Buprenorphine (partial agonist) 4-16 mg sublingual daily  <br>
 
Taper by 3% daily over next several days
===Treatment Approach===
<ref name="Senay-1977">{{Cite journal  | last1 = Senay | first1 = EC. | last2 = Dorus | first2 = W. | last3 = Goldberg | first3 = F. | last4 = Thornton | first4 = W. | title = Withdrawal from methadone maintenance. Rate of withdrawal and expectation. | journal = Arch Gen Psychiatry | volume = 34 | issue = 3 | pages = 361-7 | month = Mar | year = 1977 | doi =  | PMID = 843188 }}</ref>
====Opioid Maintenance Treatment====
----
{{familytree/start |summary=Opioid withdrawal treatment algorithm.}}
❑ '''Add nonopioid drugs:'''<br>
{{familytree | | | | | | | | | | A01 | | | | | | | | | | |A01='''Induction-day 1'''}}
:❑ [[Clonidine]] 0.2 mg every 4 hours, tapered after day 3,<ref name="O'Connor-1995">{{Cite journal  | last1 = O'Connor | first1 = PG. | last2 = Waugh | first2 = ME. | last3 = Carroll | first3 = KM. | last4 = Rounsaville | first4 = BJ. | last5 = Diagkogiannis | first5 = IA. | last6 = Schottenfeld | first6 = RS. | title = Primary care-based ambulatory opioid detoxification: the results of a clinical trial. | journal = J Gen Intern Med | volume = 10 | issue = 5 | pages = 255-60 | month = May | year = 1995 | doi =  | PMID = 7616334 }}</ref> or<br>
{{familytree | | | | | | | | | | |!| | | | | | | | | | |}}
{{familytree | | | | | | | | | | B01 | | | | | |B01=Identify the opioid(s) that the patient has been using}}
{{familytree | | | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | C01 | | | | | | C02 | | | | | | | |C01=Short acting opioids|C02=Long acting opioids}}
{{familytree | | | | | | |!| | | | | | | |!| | | | | | | | |}}
{{familytree | | | | | | D01 |-| D02 |-| D03 | | | | | | | | |D01=<div style="float: left; text-align: left">❑ Discontinue short acting opioids<br>❑ Look for withdrawal Sx (12-24 hours after last dose)</div>|D02=<div style="float: left; text-align: left">'''Withdrawal Sx absent:'''<br>❑ Reevaluate the suitability for induction </div>|D03=<div style="float: left; text-align: left">❑ Taper down long acting opioids<br>
:❑ Methadone to ≤30 mg/day
:❑ LAAM to ≤40 mg/48 hours<br>
❑ Look for withdrawal Sx:<br>
:❑ For methadone: 24+ hours after last dose
:❑ For LAAM: 48+ hours after last dose</div>}}
{{familytree | | | | | | |!| | | | | | | |!| | | | | | | | | |}}
{{familytree | | | | | | E01 |-| E02 |-| E03 | | | | | | | | | |E01=<div style="float: left; text-align: left">'''Withdrawal Sx present:'''<br>❑ Administer buprenorphine 4mg & Naloxone 1 mg<br>❑ Observe for 2+ hours</div>|E02=<div style="float: left; text-align: left">'''Withdrawal Sx relieved:'''<br>❑ Day 1 dose established<BR>❑ Send home patient<BR>❑ Patient should return on day 2 for forward induction</div>|E03=<div style="float: left; text-align: left">'''Withdrawal Sx present:'''<br>❑ Administer buprenorphine 2 mg<BR>❑ Observe 2+ hours</div>}}
{{familytree | | | | | | |!| | | | | | | |!| | | | | | | | | |}}
{{familytree | | | | | | F01 | | | | | | F02 | | | | | | | | | |F01=<div style="float: left; text-align: left">'''Withdrawal Sx not relieved:'''<br>❑ Repeat<br>
:❑ Buprenorphine 4mg (up to maximum of 8mg/24 hours)
:❑ Naloxone 1 mg (up to maximum of 2 mg/24 hours)</div>|F02=<div style="float: left; text-align: left">'''Withdrawal Sx not relieved:'''<br>❑ Repeat<br>
:❑ Buprenorphine 2mg (up to maximum of 8mg/24 hours)</div>}}
{{familytree | | | | | | |`|-|-|-|v|-|-|-|'| | | | | | | | | |}}
{{familytree | | | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | | |}}
{{familytree | | | | | | G01 | | | | | | G02 | | | | | | | | | |G01=<div style="float: left; text-align: left">'''Withdrawal Sx relieved:'''<br>❑ Day 1 dose established<BR>❑ Send home patient<BR>Patient should return on day 2 for forward induction</div>|G02=<div style="float: left; text-align: left">'''Withdrawal Sx not relieved:'''<br>Manage withdrawal Sx symptomatically<br>
:❑ [[Clonidine]] 0.2 mg every 4 hours, tapered after day 3,<ref name="O'Connor-1995">{{Cite journal  | last1 = O'Connor | first1 = PG. | last2 = Waugh | first2 = ME. | last3 = Carroll | first3 = KM. | last4 = Rounsaville | first4 = BJ. | last5 = Diagkogiannis | first5 = IA. | last6 = Schottenfeld | first6 = RS. | title = Primary care-based ambulatory opioid detoxification: the results of a clinical trial. | journal = J Gen Intern Med | volume = 10 | issue = 5 | pages = 255-60 | month = May | year = 1995 | doi =  | PMID = 7616334 }}</ref><br>'''or'''<br>
:❑ [[Lofexidine]] 0.2 mg BD daily, titrated to 1.2 mg BD daily <ref name="Strang-1999">{{Cite journal  | last1 = Strang | first1 = J. | last2 = Bearn | first2 = J. | last3 = Gossop | first3 = M. | title = Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. | journal = Am J Addict | volume = 8 | issue = 4 | pages = 337-48 | month =  | year = 1999 | doi =  | PMID = 10598217 }}</ref><br>
:❑ [[Lofexidine]] 0.2 mg BD daily, titrated to 1.2 mg BD daily <ref name="Strang-1999">{{Cite journal  | last1 = Strang | first1 = J. | last2 = Bearn | first2 = J. | last3 = Gossop | first3 = M. | title = Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. | journal = Am J Addict | volume = 8 | issue = 4 | pages = 337-48 | month =  | year = 1999 | doi =  | PMID = 10598217 }}</ref><br>
Administer chlordiazepoxide as needed
:Chlordiazepoxide as needed<BR>
----
Return next day for repeat induction attempt</div>}}
Provide general symptomatic management
{{familytree | | | | | | |!| | | | | | | | | | | | | | | | | |}}
----
{{familytree | | | | | | H01 | | | | | | | | | | | | | | | | | |H01='''Induction-day 2 forward'''}}
❑ Consult psychiatry
{{familytree | | | | | | |)|-|-|-|-|-|-| I01 | | | | | | | | |I01=<div style="float: left; text-align: left">'''On return withdrawal Sx absent:'''<br>❑ Administer a daily dose established equal to total buprenorphine & naloxone administered on previous day </div>}}
</div> }}
{{familytree | | | | | | J01 | | | | | | | | | | | | | | | | | |J01=<div style="float: left; text-align: left">'''On return withdrawal Sx present:'''<br>❑ Administer dose equal to<br>Total amount of buprenorphine & naloxone administered on previous day<br>'''+'''<br>4mg of buprenorphine (up to maximum of 12mg on day 2)<br>&<br>1mg of naloxone (up to maximum of 3mg on day 2)<br>❑ Observe 2+ hours</div> }}
{{familytree | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | |)|-|-|-|-|-|-| K01 | | | | | | | | |K01=<div style="float: left; text-align: left">'''Withdrawal Sx relieved:'''<br>❑ Daily buprenorphine & naloxone dose established </div>}}
{{familytree | | | E01 | | | | | | | | | |E01=Detoxification<ref name="Huitink-2003">{{Cite journal  | last1 = Huitink | first1 = J. | last2 = Buitelaar | first2 = D. | title = Management of drug and alcohol withdrawal. | journal = N Engl J Med | volume = 349 | issue = 4 | pages = 405-7; author reply 405-7 | month = Jul | year = 2003 | doi = | PMID = 12879900 }}</ref> }}
{{familytree | | | | | | L01 | | | | | | | | | | | | | | | | | |L01=<div style="float: left; text-align: left">'''Withdrawal Sx not relieved:'''<br>❑ Administer buprenorphine 4 mg (up to maximum of 16mg on day 2) & naloxone 1 mg (up to maximum of 4 mg on day 2)</div> }}
{{familytree | |,|-|^|-|.| | | | | | | }}
{{familytree | | | | | | |)|-|-|-|-|-|-| M01 | | | | | | | | |M01=<div style="float: left; text-align: left">'''Withdrawal Sx relieved:'''<br>❑ Daily buprenorphine & naloxone dose established </div>}}
{{familytree | F01 | | F02 | | | | | |F01=<div style="float: left; text-align: left">'''Rapid detoxification:'''<ref name="O'Connor-1997">{{Cite journal  | last1 = O'Connor | first1 = PG. | last2 = Carroll | first2 = KM. | last3 = Shi | first3 = JM. | last4 = Schottenfeld | first4 = RS. | last5 = Kosten | first5 = TR. | last6 = Rounsaville | first6 = BJ. | title = Three methods of opioid detoxification in a primary care setting. A randomized trial. | journal = Ann Intern Med | volume = 127 | issue = 7 | pages = 526-30 | month = Oct | year = 1997 | doi =  | PMID = 9313020 }}</ref><br> For a patient receiving about 8 mg of buprenorphine or 35 mg of methadone<br>❑ Detoxify while awake or under mild sedation <br> ❑ Add [[naltrexone]]<br>
{{familytree | | | | | | N01 | | | | | | | | | | | | | | | | | |N01=<div style="float: left; text-align: left">'''Withdrawal Sx not relieved:'''<br>Manage withdrawal Sx symptomatically<br>
:Day 1: 25 mg
:❑ [[Clonidine]] 0.2 mg every 4 hours, tapered after day 3,<ref name="O'Connor-1995">{{Cite journal  | last1 = O'Connor | first1 = PG. | last2 = Waugh | first2 = ME. | last3 = Carroll | first3 = KM. | last4 = Rounsaville | first4 = BJ. | last5 = Diagkogiannis | first5 = IA. | last6 = Schottenfeld | first6 = RS. | title = Primary care-based ambulatory opioid detoxification: the results of a clinical trial. | journal = J Gen Intern Med | volume = 10 | issue = 5 | pages = 255-60 | month = May | year = 1995 | doi =  | PMID = 7616334 }}</ref><br>'''or'''<br>
:❑ Days 2 to 15: 50 mg<br>
:❑ [[Lofexidine]] 0.2 mg BD daily, titrated to 1.2 mg BD daily <ref name="Strang-1999">{{Cite journal  | last1 = Strang | first1 = J. | last2 = Bearn | first2 = J. | last3 = Gossop | first3 = M. | title = Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. | journal = Am J Addict | volume = 8 | issue = 4 | pages = 337-48 | month = | year = 1999 | doi =  | PMID = 10598217 }}</ref><br>
❑ Add clonidine 0.1-0.2 mg four times daily, tapered on days 2 and 3<br>
:Chlordiazepoxide as needed<BR>
❑ Administer antiemetic agents as needed<br>❑ Administer analgesics as needed</div> |F02=<div style="float: left; text-align: left">'''Ultra rapid detoxification:'''<ref name="Presslich-1989">{{Cite journal  | last1 = Presslich | first1 = O. | last2 = Loimer | first2 = N. | last3 = Lenz | first3 = K. | last4 = Schmid | first4 = R. | title = Opiate detoxification under general anesthesia by large doses of naloxone. | journal = J Toxicol Clin Toxicol | volume = 27 | issue = 4-5 | pages = 263-70 | month = | year = 1989 | doi =  | PMID = 2600989 }}</ref><ref name="Loimer-1991">{{Cite journal  | last1 = Loimer | first1 = N. | last2 = Lenz | first2 = K. | last3 = Schmid | first3 = R. | last4 = Presslich | first4 = O. | title = Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. | journal = Am J Psychiatry | volume = 148 | issue = 7 | pages = 933-5 | month = Jul | year = 1991 | doi =  | PMID = 2053636 }}</ref><br>❑ Detoxify under heavy sedation or general anesthesia<br> ❑ Induce acute withdrawal with [[naloxone]]<br> ❑ Consider intubation and mechanical ventilation if necessary<br>❑ Administer antiemetic agents as needed<br>❑ Administer analgesics as needed </div> }}
On subsequent induction days, if the patient returns experiencing withdrawal symptoms, continue increasing dose (up to a maximum of buprenorphine 32 mg/day & naloxone 8 mg/day</div> }}
{{familytree/end}}
{{familytree/end}}
<span style="font-size:85%">'''BID:''' Twice daily </span>


==Do's==
==Do's==

Revision as of 22:45, 6 February 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]; Vendhan Ramanujam M.B.B.S [3]

Definition

Opioid withdrawal refers to the arrays of signs and symptoms following the abrupt cessation of opioids among chronic users.

Shown below is a table indicative of time to withdrawal symptoms for different opioids:[1][2]


Opioid Peak withdrawal symptoms Duration of symptoms
Heroin 36-72 hours 7-10 days
Methadone 72-96 hours 14 days or more
Buprenorphine 36-72 hours Intermediate between 7-14 days

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Opioid withdrawal is a life-threatening condition and must be treated as such irrespective of the causes.

Common Causes

Management

Diagnostic Approach

Shown below is an algorithm depicting the management of opioid withdrawal.[3]

 
 
Characterize the symptoms:
❑ Flu like illness
❑ Lacrimation
❑ Rhinorrhea
❑ Sneezing
❑ Yawning
Anorexia
Nausea
❑ Vomiting
❑ Abdominal cramps
Diarrhea
Myalgia
Arthralgia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
❑ Increased or unchanged blood pressure
❑ Increased or unchanged heart rate
❑ Increased or unchanged respiratory rate
Mydriasis
❑ Piloerection
Tremor
❑ Increased bowel sounds
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider alternative diagnosis:
❑ Alcohol withdrawal
Sedative hypnotic withdrawal
Cholinergic poisoning
Sympathomimetic intoxication
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic criteria:
❑ A. Either of the following
❑ Cessation of or reduction in opioid use that has been heavy and for several weeks or longer
❑ Administration of an opioid antagonist after a period of opioid use

❑ B. Three or more of the following (developing within minutes to several days after criterion A)

❑ Diarrhea
❑ Dysphoric mood
❑ Fever
❑ Insomnia
❑ Lacrimation or rhinorrhea
❑ Muscle aches
❑ Nausea or vomiting
❑ Pupillary dilation, piloerection, or sweating
❑ Yawning
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider treatment with:
❑ Opioid maintenance treatment
or
❑ Medically supervised withdrawal (detoxification)
 
 
 
 
 
 
 
 
 
 

Treatment Approach

Opioid Maintenance Treatment

 
 
 
 
 
 
 
 
 
Induction-day 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identify the opioid(s) that the patient has been using
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Short acting opioids
 
 
 
 
 
Long acting opioids
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Discontinue short acting opioids
❑ Look for withdrawal Sx (12-24 hours after last dose)
 
Withdrawal Sx absent:
❑ Reevaluate the suitability for induction
 
❑ Taper down long acting opioids
❑ Methadone to ≤30 mg/day
❑ LAAM to ≤40 mg/48 hours

❑ Look for withdrawal Sx:

❑ For methadone: 24+ hours after last dose
❑ For LAAM: 48+ hours after last dose
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Withdrawal Sx present:
❑ Administer buprenorphine 4mg & Naloxone 1 mg
❑ Observe for 2+ hours
 
Withdrawal Sx relieved:
❑ Day 1 dose established
❑ Send home patient
❑ Patient should return on day 2 for forward induction
 
Withdrawal Sx present:
❑ Administer buprenorphine 2 mg
❑ Observe 2+ hours
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Withdrawal Sx not relieved:
❑ Repeat
❑ Buprenorphine 4mg (up to maximum of 8mg/24 hours)
❑ Naloxone 1 mg (up to maximum of 2 mg/24 hours)
 
 
 
 
 
Withdrawal Sx not relieved:
❑ Repeat
❑ Buprenorphine 2mg (up to maximum of 8mg/24 hours)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Withdrawal Sx relieved:
❑ Day 1 dose established
❑ Send home patient
❑ Patient should return on day 2 for forward induction
 
 
 
 
 
Withdrawal Sx not relieved:
Manage withdrawal Sx symptomatically
Clonidine 0.2 mg every 4 hours, tapered after day 3,[4]
or
Lofexidine 0.2 mg BD daily, titrated to 1.2 mg BD daily [5]
❑ Chlordiazepoxide as needed
❑ Return next day for repeat induction attempt
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Induction-day 2 forward
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On return withdrawal Sx absent:
❑ Administer a daily dose established equal to total buprenorphine & naloxone administered on previous day
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On return withdrawal Sx present:
❑ Administer dose equal to
Total amount of buprenorphine & naloxone administered on previous day
+
4mg of buprenorphine (up to maximum of 12mg on day 2)
&
1mg of naloxone (up to maximum of 3mg on day 2)
❑ Observe 2+ hours
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Withdrawal Sx relieved:
❑ Daily buprenorphine & naloxone dose established
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Withdrawal Sx not relieved:
❑ Administer buprenorphine 4 mg (up to maximum of 16mg on day 2) & naloxone 1 mg (up to maximum of 4 mg on day 2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Withdrawal Sx relieved:
❑ Daily buprenorphine & naloxone dose established
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Withdrawal Sx not relieved:
Manage withdrawal Sx symptomatically
Clonidine 0.2 mg every 4 hours, tapered after day 3,[4]
or
Lofexidine 0.2 mg BD daily, titrated to 1.2 mg BD daily [5]
❑ Chlordiazepoxide as needed
❑ On subsequent induction days, if the patient returns experiencing withdrawal symptoms, continue increasing dose (up to a maximum of buprenorphine 32 mg/day & naloxone 8 mg/day
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Do's

  • Treat the patient for a duration of 10 days for heroin withdrawal and 14 days for methadone withdrawal.
  • Restrict methadone and other opioid agonists to inpatient settings or licensed programs.
  • Administer chlordiazepoxide, a longer-acting benzodiazepine to augment clonidine in patients with insomnia or muscle cramps.[4]
  • Detoxification should be undertaken only under clinicians with special training, equipment, or both.
  • Start buprenorphine at least two days before starting naltrexone during detoxification.

Dont's

  • Do not abruptly stop drugs that are being used to treat withdrawal.

References

  1. Jasinski, DR.; Pevnick, JS.; Griffith, JD. (1978). "Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction". Arch Gen Psychiatry. 35 (4): 501–16. PMID 215096. Unknown parameter |month= ignored (help)
  2. Opiods: detoxification. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. 2nd ed. Washington, D.C.: American Psychiatric Press, 1999:251-69.>
  3. Huitink, J.; Buitelaar, D. (2003). "Management of drug and alcohol withdrawal". N Engl J Med. 349 (4): 405–7, author reply 405-7. PMID 12879900. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 4.2 O'Connor, PG.; Waugh, ME.; Carroll, KM.; Rounsaville, BJ.; Diagkogiannis, IA.; Schottenfeld, RS. (1995). "Primary care-based ambulatory opioid detoxification: the results of a clinical trial". J Gen Intern Med. 10 (5): 255–60. PMID 7616334. Unknown parameter |month= ignored (help)
  5. 5.0 5.1 Strang, J.; Bearn, J.; Gossop, M. (1999). "Lofexidine for opiate detoxification: review of recent randomised and open controlled trials". Am J Addict. 8 (4): 337–48. PMID 10598217.


Template:WikiDoc Sources